Substituted 2-aryl-4-arylaminopyrimidines and analogs as...

Details Substituted 2-aryl-4-arylaminopyrimidines and analogs as... Substituted 2-aryl-4-arylaminopyrimidines and analogs as...

2007-06-05

2007-06-05

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S241000, C544S180000, C544S326000, C544S328000

Reexamination Certificate

active

10704448

ABSTRACT:
The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I:wherein A, Ar1, Ar2, R1and R3are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

REFERENCES:
patent: 3989816 (1976-11-01), Rajadhyaksha
patent: 4041030 (1977-08-01), Fauran et al.
patent: 4444762 (1984-04-01), Rajadhyaksha
patent: 5250530 (1993-10-01), Giencke et al.
patent: 5935966 (1999-08-01), Suto et al.
patent: 6103737 (2000-08-01), Cocuzza et al.
patent: 6156755 (2000-12-01), Geisen
patent: 6403599 (2002-06-01), Chen et al.
patent: 6610677 (2003-08-01), Davies et al.
patent: 6716851 (2004-04-01), Cai et al.
patent: 6956047 (2005-10-01), Chen
patent: 0 407 899 (1991-01-01), None
patent: 0 629 622 (1994-12-01), None
patent: 0 640 599 (1995-03-01), None
patent: 63-107966 (1988-05-01), None
patent: WO 95/06473 (1995-03-01), None
patent: 95-10506 (1995-04-01), None
patent: WO 96/20721 (1996-07-01), None
patent: WO 97/09315 (1997-03-01), None
patent: WO 98/38171 (1998-09-01), None
patent: WO 99/18856 (1999-05-01), None
patent: WO 00/27824 (2000-05-01), None
patent: WO 01/25220 (2001-04-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 02/47690 (2002-06-01), None
Cieplik, J. et. al., Chemical Abstract, vol. 120, Abstract # 298579.
Batteux, F., et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, American Association of Immunologists (Jan. 1999).
Boirivant, M., et al., “Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastroent. 116:557-565, American Gastroenterological Association (Mar. 1999).
Calabresi, P. and Chabner, B.A., “Section X. Chemotherapy of Neoplastic Diseases,” inGoodman&Gilman's The Pharmacological Basis of Therapeutics,Wonsiewicz, M.J. and McCurdy, P., eds., McGraw-Hill Companies, Inc., New York, New York, pp. 1225-1287 (1996).
Coven, T.R., et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed. 15:22-27, Munksgaard (Feb. 1999).
Ellis, R.E., et al., “Mechanisms and Functions of Cell Death,”Annu. Rev. Cell Biol. 7:663-698, Annual Reviews, Inc. (1991).
Ellis, R.E. and Horvitz, H.R., “TwoC. elegansgenes control the programmed deaths of specific cells in the pharynx,”Develop. 112:591-603, The Company of Biologists Ltd. (1991).
Friesen, C., et al., “Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nature Med. 2:574-577, Nature Publishing Group (1996).
Glücksmann, A., “Cell Deaths in Normal Vertebrate Ontogeny,”Biological Reviews Camb. Philos. Soc. 26:59-86, The University Press (1951).
Glücksmann, A., “Cell death in normal development,”Arch. Biol. 76:419-437, Vaillant-Carmanne (1965).
Greenwald, R.B., et al., “Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds,”J. Med. Chem. 42:3657-3667, American Chemical Society (Aug. 1999).
Heenen, M., et al., “Methotrexate induces apoptotic cell death in human keratinocytes,”Arch. Dermatol. Res. 290:240-245, Springer-Verlag (1998).
Infante, A.J., et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Ped. 133:629-633, Mosby, Inc. (1998).
Leu, Y.-L., et al., “Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT),”J. Med. Chem. 42:3623-3628, American Chemical Society (Aug. 1999).
López-Hoyos, M., et al., “Regulation of B cell apoptosis by Bcl-2 and Bcl-XLand its role in the development of autoimmune diseases (Review),”Intl. J. Mol. Med. 1:475-483, D.A. Spandidos (1998).
Los, M., et al., “Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases),”Blood 90:3118-3129, W.B. Saunders Company (1997).
Ohsako, S. and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Stockton Press (Jan. 1999).
O'Reilly, L.A. and Strasser, A., “Apoptosis and autoimmune disease,”Inflamm. Res. 48:5-21, Birkhäuser Verlag (Jan. 1999).
Orrenius, S., “Apoptosis: molecular mechanisms and implications for human disease,”J. Int. Med. 237:529-536, Blackwell Science Ltd. (1995).
Ozawa, M., et al., “312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions,”J. Exp. Med. 189:711-718, The Rockefeller University Press (Feb. 1999).
Pettit, G.R. and Lippert III, J.W., “Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs,”Anti-Cancer Drug Des. 15:203-216, Oxford University Press (Jun. 2000).
Reed, J.C., “Bcl-2 Family Proteins,” inApoptosis and Cancer Chemotherapy,Hickman, J.A. and Dive, C., eds., Humana Press, Totowa, NJ, pp. 99-116 (Apr. 1999).
Savill, J., “Apoptosis in resolution of inflammation,”J. Leuk. Biol. 61:375-380, Society for Leukocyte Biology (1997).
Schmitt, E., et al., “The Bcl-xL and Bax-α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation,”Biochem. Cell Biol. 75:301-314, National Research Council of Canada (1997).
Thornberry, N.A., “The caspase family of cysteine proteases,”British Med. Bull. 53:478-490, The Royal Society of Medicine Press Ltd. (1996).
Thornberry, N.A., “Caspases: key mediators of apoptosis,”Chem.&Biol. 5:R97-R103, Current Biology, Ltd. (1998).
Vaishnaw, A.K., et al., “The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations,”J. Clin. Invest. 103:355-363, American Society for Clinical Investigation (Feb. 1999).
Vaux, D.L., et al., “An Evolutionary Perspective on Apoptosis,”Cell 76:777-779, Cell Press (1994).
Wakisaka, S., et al., “Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA),”Clin. Exp. Immunol. 114:119-128, Blackwell Science (1998).
Wyllie, A.H., et al., “Cell Death: The Significance of Apoptosis,”Intl. Rev. Cyt. 68:251-304, Academic Press (1980).
Wyllie, A.H., “Cell death: a new classification separating apoptosis from necrosis,” inCell death in biology and pathology,Bowen, I.D. and Lockshin, R.A., eds. Chapman and Hall, London, England, pp. 9-34 (1981).
Espace English language abstract of Japanese Patent Publication No. JP 63-107966 (Document AO2) available at http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=JP63107966&F=0.
Supplementary Partial European Search Report for European Patent Application No. EP 01 99 0048.9, mailed May 6, 2005, European Patent Office, The Hague.
Zhou, T., et al., “Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases,”Nature Med. 5:42-48, Nature Publishing Group (Jan. 1999).
International Search Report for International Patent Application No. PCT/US01/47498, mailed May 30, 2002.
Dialog File 351, Accession No. 8512057, Derwent WPI English language abstract for EP 0 407 899 A2, published Jan. 16, 1991, Derwent Information Ltd, 2002 (3 pages).

Affiliated with

Also associated with

Rating

Substituted 2-aryl-4-arylaminopyrimidines and analogs as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted 2-aryl-4-arylaminopyrimidines and analogs as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2-aryl-4-arylaminopyrimidines and analogs as... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3884738